Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by U.S. Capital Wealth Advisors LLC

U.S. Capital Wealth Advisors LLC raised its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 91.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,174 shares of the biotechnology company’s stock after acquiring an additional 21,129 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Viking Therapeutics were worth $1,778,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of VKTX. Blue Trust Inc. acquired a new position in Viking Therapeutics in the third quarter valued at $26,000. GAMMA Investing LLC boosted its stake in Viking Therapeutics by 124.6% in the third quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 243 shares in the last quarter. Gilliland Jeter Wealth Management LLC acquired a new position in Viking Therapeutics in the third quarter valued at $32,000. Stone House Investment Management LLC boosted its stake in Viking Therapeutics by 66.7% in the third quarter. Stone House Investment Management LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 200 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV raised its holdings in shares of Viking Therapeutics by 84.3% in the third quarter. Massmutual Trust Co. FSB ADV now owns 553 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 253 shares during the last quarter. Institutional investors and hedge funds own 76.03% of the company’s stock.

Insider Activity

In related news, Director Lawson Macartney sold 2,000 shares of Viking Therapeutics stock in a transaction on Friday, November 8th. The shares were sold at an average price of $68.67, for a total transaction of $137,340.00. Following the transaction, the director now owns 47,965 shares in the company, valued at approximately $3,293,756.55. The trade was a 4.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Brian Lian sold 194,490 shares of Viking Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $42.75, for a total transaction of $8,314,447.50. Following the transaction, the chief executive officer now owns 2,366,570 shares in the company, valued at $101,170,867.50. The trade was a 7.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 301,014 shares of company stock valued at $12,920,189 in the last ninety days. Company insiders own 4.70% of the company’s stock.

Viking Therapeutics Stock Down 3.8 %

Shares of NASDAQ VKTX opened at $31.52 on Tuesday. Viking Therapeutics, Inc. has a 52-week low of $22.69 and a 52-week high of $99.41. The firm has a fifty day moving average of $41.76 and a 200-day moving average of $54.45. The stock has a market capitalization of $3.51 billion, a PE ratio of -33.89 and a beta of 0.90.

Analyst Ratings Changes

A number of brokerages have recently commented on VKTX. HC Wainwright reaffirmed a “buy” rating and issued a $102.00 target price on shares of Viking Therapeutics in a report on Friday, January 17th. StockNews.com raised shares of Viking Therapeutics to a “sell” rating in a report on Tuesday, October 15th. Piper Sandler started coverage on shares of Viking Therapeutics in a report on Monday, December 2nd. They set an “overweight” rating and a $74.00 price target for the company. B. Riley initiated coverage on shares of Viking Therapeutics in a report on Friday, November 22nd. They set a “buy” rating and a $109.00 price target for the company. Finally, William Blair restated an “outperform” rating on shares of Viking Therapeutics in a research report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $106.75.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.